• 1
    Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin Oncol 1996; 23: 28191.
  • 2
    Roukos DH. Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000; 26: 24355.
  • 3
    Macdonald JS. Advances in the therapy of gastric cancer. Gastric Cancer 2002; 5 (Suppl. 1): 3540.
  • 4
    Van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 16437.
  • 5
    Bjorkman PA, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatiblity antigen, HLA-A2. Nature 1987; 329: 50612.
  • 6
    Sadanaga N, Nagashima H, Mashino K et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin Cancer Res 2001; 7: 227784.
  • 7
    Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastasis in advanced stage IV melanoma. J Exp Med 1999; 190: 166978.
  • 8
    Rentzsch C, Kayser S, Stumm S et al. Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells. Clin Cancer Res 2003; 9: 437686.
  • 9
    Kono K, Takahashi A, Sugai H et al. Dendritic cells pulsed with HER-2/neu-derived peptide can induce specific T-cell responses in patients with gastric cancer. Clin Cancer Res 2002; 8: 3394400.
  • 10
    Boon T, Old LJ. Cancer tumor antigens. Curr Opin Immunol 1997; 9: 6813.
  • 11
    Sasada T, Takedatsu H, Azuma K et al. Immediate early response gene X-1, a stress-inducible antiapoptotic gene, encodes cytotoxic T-lymphocyte (CTL) epitopes capable of inducing human leukocyte antigen-A33-restricted and tumor-reactive CTLs in gastric cancer patients. Cancer Res 2004; 64: 28828.
  • 12
    Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 191418.
  • 13
    Sahin U, Tureci O, Sxhmitt H et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92: 118103.
  • 14
    Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y, Tahara H. Ring finger protein (RNF) 43 as a new target for cancer immunotherapy. Clin Can Res 2004; 10: 857786.
  • 15
    Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001; 50: 315.
  • 16
    Stevanovic S. Identification of tumor associated T-cell epitopes for vaccine development. Nature Rev 2002; 2: 17.
  • 17
    Kawakami Y, Eliyahu SC, Jennings K et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154: 39618.
  • 18
    Rosenberg SA, Yang JC, Schwartentruber DJ et al. Immunologic and therapeutic evaluation of synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 3217.
  • 19
    Panelli MC, Wunderlich J, Jeffries J et al. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 2000; 23: 48798.
  • 20
    Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 32832.
  • 21
    Butterfield LH, Ribas A, Dissette VB et al. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 2003; 9: 9981008.
  • 22
    Strome SE, Voss S, Wilcox R et al. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res 2002; 62: 18849.
  • 23
    Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji BH. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996; 56: 247983.
  • 24
    Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H. Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild type p53. Br J Cancer 2001; 84: 10527.
  • 25
    Lander ES, Linton LM, Chen YJ et al. The genome international sequencing consortium: initial sequencing and analysis of the human genome. Nature 2001; 409: 860921.
  • 26
    Lu J, Celis E. Use of predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes. Cancer Res 2000; 60: 52237.
  • 27
    Parker KC, Bednarek MA, Hull LK et al. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol 1992; 149: 35807.
  • 28
    Solache A, Morgan CL, Dodi AI et al. Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol 1999; 163: 55128.
  • 29
    Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res 2003; 63: 41128.
  • 30
    Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogenic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333: 103844.
  • 31
    Hasegawa S, Furukawa Y, Li M et al. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23 040 genes. Cancer Res 2002; 62: 70127.
  • 32
    Smith MH, Nuara AA, Egen JG, Shirjani DB, Lam KS, Grimes WJ. Baculoviral expressed HLA-class I heavy chains used to screen a synthetic peptide library for allele-specific peptide binding motifs. Mol Immunol 1998; 35: 103343.
  • 33
    Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific T lymphocyte lines. J Exp Med 1995; 181: 210917.
  • 34
    Watanabe T, Suda T, Tsunoda T et al. Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastro-intestinal and hepatocellular carcinomas. Cancer Sci 2005; 96: 498506.
  • 35
    Way G, Morrice N, Smythe C, O'Sullivan AJ. Purification of and identification of secernin, a novel cytosolic protein that regulates exocytosis in mast cells. Mol Biol Cell 2002; 13: 334452.
  • 36
    Aridor M, Rajmilevich G, Beaven MA, Sagi-Eisenberg R. Activation of exocytosis by the heterotrimeric G protein Gi3. Science 1993; 262: 156972.
  • 37
    Pinxteren JA, O'Sullivan AJ, Tatham PE, Gomperts BD. Regulation of exocytosis from rat peritoneal mast cells by G protein beta gamma-subunits. EMBO J 1998; 17: 62108,.
  • 38
    O'Sullivan AJ, Brown AM, Freeman HN, Gomperts BD. Purification and identification of FOAD-II, a cytosolic protein that regulates secretion in streptolysin-O permeabilized mast cells, as a rac/rhoGDI complex. Mol Biol Cell 1996; 7: 397408.
  • 39
    Price LS, Norman JC, Ridley AJ, Koffer A. The small GTPases Rac and Rho as regulators of secretion in mast cells. Curr Biol 1995; 5: 6873.
  • 40
    Brown AM, O'Sullivan AJ, Gomperts BD. Induction of exocytosis from permeabilized mast cells by the guanosine triphosphatases Rac and Cdc42. Mol Biol Cell 1998; 9: 105363.
  • 41
    Bendnarek MA, Sauma SY, Gammon MC et al. The minimum peptide epitope from the influenza virus matrix protein: extra and intracellular loading of HLA-A2. J Immunol 1991; 147: 404753.
  • 42
    Keogh E, Fikes J, Southwood S, Celis E, Chesnut R, Sette A. Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. J Immunol 2001; 167: 78796.
  • 43
    Sette A, Vitiello A, Reherman B et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994; 153: 558692.
  • 44
    Tourdot S, Oukka M, Manuguerra JC et al. A new approach to enhancing the immunogenicity of peptide with low MHC-class I affinity: application in antiviral vaccination. J Immunol 1997; 159: 23918.
  • 45
    Sarobe P, Pendleton CD, Akatsuka T et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. J Clin Invest 1998; 102: 123948.
  • 46
    Slansky JE, Rattis FM, Boyd LF et al. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity 2000; 13: 52938.
  • 47
    Ruppert J, Sidney J, Celis E, Kubo RT, Grey HM, Sette A. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 1993; 74: 92937.
  • 48
    Clay TM, Custer MC, Mckee MD et al. Changes in the fine specificity of gp100 (209–217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J Immunol 1999; 162: 174955.
  • 49
    Dionne SO, Smith MH, Marincola FM, Lake DF. Functional characterization of CTL against gp100 altered peptide ligands. Cancer Immuno Immunother 2003; 52: 199206.
  • 50
    Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996; 14: 127.
  • 51
    Yang S, Linette GP, Longerich S, Haluska FG. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209–2M is correlated to TCR avidity. J Immunol 2002; 169: 5319.
  • 52
    Dionne SO, Myers CE, Smith MH, Lake DF. Her-2/neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell receptor interaction. Cancer Immuno Immunother 2004; 53: 30714.